Prognosis
Regeneron Antibody Cocktail Used by Trump Faces Patent Suit
- Pfizer, BioNTech also sued over tech used to develop vaccine
- Allele Biotechnology filed claims over its fluorescent protein
This article is for subscribers only.
The Regeneron Pharmaceuticals Inc. “antibody cocktail” given to President Donald Trump to treat his Covid-19 symptoms was developed with the unauthorized use of a fluorescent protein, according to a lawsuit by a California company that patented the technology.
Allele Biotechnology and Pharmaceuticals Inc., a closely held company founded in 1999, sued Regeneron on Monday in White Plains, New York, seeking royalties for the use of its mNeonGreen protein in developing the experimental treatment. A separate federal lawsuit was filed in California against Pfizer Inc. and BioNTech SE, partners in the race to develop a Covid-19 vaccine.